SCHEMBL2792174

SCHEMBL2792174

O=C(O)c1ccc(C(=O)C2CCCN2C(=O)OCc2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PREP P48147 4/20 0.59
NPSR1 Q6W5P4 1/20 0.58
KLK7 P49862 1/20 0.57
KLK5 Q9Y337 1/20 0.57
CTRB1 P17538 1/20 0.56
TSHR P16473 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KMT2A Q03164 1/20 0.54
KDM4E B2RXH2 1/20 0.54
LMNA P02545 1/20 0.54
GFER P55789 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ALDH1A1 P00352 2/20 0.53
KDM1A O60341 1/20 0.53
RCOR1 Q9UKL0 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10223106 0.91 PREP (0.59) PREPNPSR1KLK7KLK5CTRB1
SCHEMBL10634764 0.90 PREP (0.58) PREPNPSR1KLK7KLK5CTRB1
SCHEMBL7276747 0.90 KDM4E (0.62) PREPNPSR1KLK7KLK5CTRB1
SCHEMBL2793443 0.89 NPSR1 (0.62) PREPNPSR1CTRB1TSHRL3MBTL1
SCHEMBL7326760 0.86 FKBP1A (0.66) PREPNPSR1KLK7KLK5CTRB1
SCHEMBL16272917 0.86 FKBP1A (0.66) PREPNPSR1KLK7KLK5CTRB1
SCHEMBL8747162 0.85 KLK7 (0.62) PREPNPSR1KLK7KLK5CTRB1
SCHEMBL839568 0.85 KLK7 (0.62) PREPNPSR1KLK7KLK5CTRB1
SCHEMBL8747160 0.85 KLK7 (0.62) PREPNPSR1KLK7KLK5CTRB1
SCHEMBL205223 0.84 PREP (0.67) PREPNPSR1KLK7KLK5CTRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190788-A1 Amide derivatives as kinase inhitors DEVGEN N.V. (BE) 2010-07-29 US disclosed
US-20100168102-A9 Amide Derivatives as Kinase Inhibitors DEVGEN NV (BE) 2010-07-01 US disclosed
US-20090118283-A1 Amide Derivatives as Kinase Inhibitors DEVGEN NV (BE) 2009-05-07 US disclosed
EP-1907362-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS Devgen NV (BE) 2008-04-09 EP disclosed
EP-1907361-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS Devgen N.V. (BE) 2008-04-09 EP disclosed
WO-2007006547-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 WO disclosed
WO-2007006546-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168102-A9 Amide Derivatives as Kinase Inhibitors MAP3K1, CDK1, CDK2 PREP 1828/4885NPSR1 886/4885KLK7 2220/4885
US-20100190788-A1 Amide derivatives as kinase inhitors MAP3K1, MAPK1, MAP3K21 PREP 1235/4885NPSR1 1532/4885KLK7 3297/4885
US-20090118283-A1 Amide Derivatives as Kinase Inhibitors MAP3K1, CDK1, CDK2 PREP 1828/4885NPSR1 886/4885KLK7 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.